Treatment of acute kidney injury with continuous renal replacement therapy and cytokine adsorber (CytoSorb®) in critically ill patients with COVID-19.
COVID‐19
acute kidney injury
continuous renal replacement therapy
cytokine adsorption
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
revised:
06
06
2024
received:
16
10
2023
accepted:
14
06
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
3
7
2024
Statut:
aheadofprint
Résumé
This retrospective study aimed to evaluate the 30 and 60-day survival of critically ill patients with COVID-19 and AKI. Inflammatory and biochemical biomarkers, length of intensive care unit (ICU) stay and mortality at Day 30 and Day 60 after ICU admission were analyzed. A total of 44 patients treated with continuous renal replacement therapy (CRRT) with cytokine adsorber (CA group) were compared to 58 patients treated with CRRT alone (non-CA group). Patients in CA group were younger, had better preserved kidney function prior to the beginning of CRRT and had higher levels of interleukin-6. There were no statistically significant differences in their comorbidities and in other measured biomarkers between the two groups. The number of patients who died 60 days after ICU admission was statistically significantly higher in non-CA group (p = 0.029). Treatment with CRRT and cytokine adsorber may have positively influenced 60-day survival in our COVID-19 ICU patients with AKI.
Identifiants
pubmed: 38958006
doi: 10.1111/1744-9987.14182
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis and Japanese Society for Apheresis.
Références
Chávez‐Valencia V, Orizaga‐de‐la‐Cruz C, Lagunas‐Rangel FA. Acute kidney injury in COVID‐19 patients: pathogenesis, clinical characteristics, therapy, and mortality. Diseases. 2022;10(3):53.
Głowacka M, Lipka S, Młynarska E, Franczyk B, Rysz J. Acute kidney injury in COVID‐19. Int J Mol Sci. 2021;22(15):8081.
León‐Román J, Agraz I, Vergara A, Ramos N, Toapanta N, García‐Carro C, et al. COVID‐19 infection and renal injury: where is the place for acute interstitial nephritis disease? Clin Kidney J. 2022;15(9):1698–1704.
Piko N, Ekart R, Hojs R, Bevc S. COVID‐19‐associated nephropathy: an emerging clinical entity. EMJ Nephrol. 2022;10(1):84–89. https://doi.org/10.33590/emjnephrol/22-0005
Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). J Pathol. 2020;251(3):228–248.
Chong WH, Saha BK. Relationship between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and the etiology of acute kidney injury (AKI). Am J Med Sci. 2021;361(3):287–296.
Chen G, Zhou Y, Ma J, Xia P, Qin Y, Li X. Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID‐19 patients? Ren Fail. 2020;42(1):483–488.
Hu B, Huang S, Yin L. The cytokine storm and COVID‐19. J Med Virol. 2021;93(1):250–256.
Shemies RS, Nagy E, Younis D, Sheashaa H. Renal replacement therapy for critically ill patients with COVID‐19‐associated acute kidney injury: a review of current knowledge. Ther Apher Dial. 2022;26(1):15–23.
Peerapornratana S, Manrique‐Caballero CL, Gómez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 2019;96(5):1083–1099.
Singer M, Deutschman CS, Seymour CW, Shankar‐Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis‐3). JAMA. 2016;315(8):801–810.
Ankawi G, Xie Y, Yang B, Xie Y, Xie P, Ronco C. What have we learned about the use of Cytosorb Adsorption columns? Blood Purif. 2019;48:196–202.
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–1247.
CytoSorb Home. CytoSorbents Europe GmbH. 2023. https://cytosorb-therapy.com/en/
Ruiz‐Rodríguez JC, Molnar Z, Deliargyris EN, Ferrer R. The use of CytoSorb therapy in critically ill COVID‐19 patients: review of the rationale and current clinical experiences. Crit Care Res Prac. 2021;2021:7769516.
Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, et al. AKI treated with renal replacement therapy in critically ill patients with COVID‐19. J Am Soc Nephrol. 2021;32(1):161–176.
Bezerra R, Teles F, Mendonca PB, Damte T, Likaka A, Ferrer‐Miranda E, et al. Outcomes of critically ill patients with acute kidney injury in COVID‐19 infection: an observational study. Ren Fail. 2021;43(1):911–918.
Pannu N, Noel GR. Renal replacement therapy in the intensive care unit. Ther Clin Risk Manag. 2005;1(2):141–150.
Asgharpour M, Mehdinezhad H, Bayani M, Zavareh MSH, Hamidi SH, Akbari R, et al. Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID‐19). BMC Nephrol. 2020;21(1):356.
Mehta Y, Mehta C, Kumar A, George JV, Gupta A, Nanda S, et al. Experience with hemoadsorption (CytoSorb®) in the management of septic shock patients. World J Crit Care Med. 2020;9(1):1–12.
Schädler D, Pausch C, Heise D, Meier‐Hellmann A, Brederlau J, Weller N, et al. The effect of novel extracorporeal cytokine hemoadsorption device on IL‐6 elimination in septic patients: a randomized controlled trial. PLoS One. 2017;12(10):e0187015.
Supady A, Weber E, Rieder M, Lother A, Niklaus T, Zahn T, et al. Cytokine adsorption in patients with severe COVID‐19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open‐label, randomised, controlled trial. Lancet Respir Med. 2021;9(7):755–762.
Kang K, Luo Y, Gao Y, Zhang J, Wang C, Fei D, et al. Continuous renal replacement therapy with oXiris filter may not be an effective resolution to alleviate cytokine release syndrome in non‐AKI patients with severe and critical COVID‐19. Front Pharmacol. 2022;13:817793.
Jakopin E, Hren M, Knehtl M, Dvorsak B, Hojs N, Zorman T, et al. P1095. Use of cytokine adsorbing membranes in patients with acute renal failure in intensive care units. Nephrol Dialy Transplant. 2020;35:gfaa142.
Tan BWL, Tan BWQ, Tan AIM, Schriver ER, Gutierrez‐Sacristán A, Das P, et al. Long‐term kidney function recovery and mortality after COVID‐19‐associated acute kidney injury: an international multi‐centre observational cohort study. EclinicalMedicine. 2022;55:101724.
Burke E, Haber E, Pike CW, Sonti R. Outcomes of renal replacement therapy in the critically ill with COVID‐19. Med Intensiva. 2021;45(6):325–331.
Ng JH, Hirsch JS, Hazzan A, Wanchoo R, Shah HH, Malieckal DA, et al. Outcomes among patients hospitalized with COVID‐19 and acute kidney injury. Am J Kidney Dis. 2021;77(2):204–215.
Huang AC, Lee TY, Ko MC, Huang CH, Wang TY, Lin TY, et al. Fluid balance correlates with clinical course of multiple organ dysfunction syndrome and mortality in patients with septic shock. PLoS One. 2019;14(12):e0225423.
Bennett VA, Vidouris A, Cecconi M. Effects of fluids on the macro‐ and microcirculations. Crit Care. 2018;22(1):74.
Xiang H, Song B, Zhang Y, Zhang J, Xiong J. The effectiveness of continuous renal replacement therapy in critical COVID‐19 patients with cytokine release syndrome: a retrospective, multicenter, descriptive study from Wuhan. China Aging (Albany NY). 2021;13(7):9243–9252.